In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Zevra Therapeutics Inc (NASDAQ: ZVRA) was $8.66 for the day, up 0.58% from the previous closing price of $8.61. In other words, the price has increased by $0.58 from its previous closing price. On the day, 0.55 million shares were traded.
Ratios:
Our analysis of ZVRA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.93 and its Current Ratio is at 3.02. In the meantime, Its Debt-to-Equity ratio is 1.51 whereas as Long-Term Debt/Eq ratio is at 1.49.
On October 07, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $20.
Maxim Group reiterated its Buy rating for the stock on September 24, 2024, while the target price for the stock was revised from $18 to $25.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 28 ’25 when Watton Corey Michael bought 300 shares for $7.84 per share. The transaction valued at 2,352 led to the insider holds 1,800 shares of the business.
Bode John B bought 10,000 shares of ZVRA for $79,624 on Mar 19 ’25. The Director now owns 40,000 shares after completing the transaction at $7.96 per share. On Feb 13 ’25, another insider, Sangiovanni Timothy J., who serves as the SVP, Finance & Corp Controller of the company, sold 3,000 shares for $7.86 each. As a result, the insider received 23,588 and left with 16,341 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 11.67 while its Price-to-Book (P/B) ratio in mrq is 11.54.
Stock Price History:
Over the past 52 weeks, ZVRA has reached a high of $9.76, while it has fallen to a 52-week low of $4.20. The 50-Day Moving Average of the stock is 13.24%, while the 200-Day Moving Average is calculated to be 9.01%.
Shares Statistics:
A total of 54.68M shares are outstanding, with a floating share count of 54.08M. Insiders hold about 1.10% of the company’s shares, while institutions hold 65.40% stake in the company.
Earnings Estimates
Investors are keenly observing as 7.0 analysts analyze and rate the current performance of Zevra Therapeutics Inc (ZVRA) in the stock market.The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.04 and low estimates of -$0.1.
Analysts are recommending an EPS of between $2.42 and -$0.34 for the fiscal current year, implying an average EPS of $1.09. EPS for the following year is $1.44, with 7.0 analysts recommending between $5.84 and $0.05.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $24.3M to a low estimate of $20.6M. As of the current estimate, Zevra Therapeutics Inc’s year-ago sales were $4.45MFor the next quarter, 5 analysts are estimating revenue of $24.29M. There is a high estimate of $26.1M for the next quarter, whereas the lowest estimate is $22.2M.
A total of 5 analysts have provided revenue estimates for ZVRA’s current fiscal year. The highest revenue estimate was $99.4M, while the lowest revenue estimate was $87M, resulting in an average revenue estimate of $94.27M. In the same quarter a year ago, actual revenue was $23.61MBased on 7 analysts’ estimates, the company’s revenue will be $206.42M in the next fiscal year. The high estimate is $451.5M and the low estimate is $114.6M.
